News

Positive Phase 3 Trial Data of COPD Therapy Revefenacin Reported by Theravance and Mylan

Theravance Biopharma and Mylan recently reported positive Phase 3 trial data on the effectiveness of the drug revefenacin (TD-4208) for the treatment of chronic obstructive pulmonary disease (COPD). Revefenacin is an investigational long-acting muscarinic antagonist (LAMA) and the first once-daily nebulized bronchodilator in development to treat COPD. The drug will be…

New Drug Application for Sunovion’s COPD Therapy Accepted by FDA

The FDA recently accepted a New Drug Application (NDA) for Sunovion’s investigational treatment SUN-101 (glycopyrrolate) administered by the eFlow nebulizer to treat adults with chronic obstructive pulmonary disease (COPD). Although the FDA’s acceptance of the NDA for review does not guarantee approval, it is a crucial step in the drug approval process. Sunovian…

Free Program Helps COPD Patients Start New Inhaled Therapy

Boehringer Ingelheim Pharmaceuticals and Ashfield Healthcare have launched a new and free patient support program. Called ‘STIOLTO Promise,’ the no-cost offer provides 30 days of medicine, resources, and at-home counseling via respiratory specialists for patients with chronic obstructive pulmonary disease (COPD) who are prescribed STIOLTO RESPIMAT. STIOLTO RESPIMAT was approved in May 2015 for…

ResApp Reports New Positive Trial Results in COPD, Other Lung Diseases

ResApp Health, an Australian company developing digital healthcare solutions for respiratory conditions, recently reported additional preliminary positive results of its adult clinical trial assessing the company’s app for the diagnosis of different lung diseases, including chronic obstructive pulmonary fibrosis (COPD). According to a ResApp press release, the results showed that the…

COPD May Worsen with Indoor Air Pollution Combined with High Temps

A new research study suggests that high indoor temperatures could worsen the symptoms of chronic obstructive pulmonary disease (COPD), particularly in homes with high levels of air pollutants. Johns Hopkins University researchers conducted a longitudinal study including 69 patients with moderate-to-severe COPD during the hottest days of the year. The results of…

How Resveratrol, Feature of Red Wine, Works to Fight Bacteria-linked Lung Inflammation Detailed in Study

A component of red wine and grapes, resveratrol, was seen to halt the pathogen-induced inflammation common in respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The study, “Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short,” was published in the online…

Real-world Study of COPD Patients Shows Nondrug Aerobika Device Reduces Exacerbations

Positive results from a real-world study were recently presented evaluating the effectiveness of the Aerobika Oscillating PEP nondrug device in reducing chronic obstructive pulmonary disease (COPD) exacerbations. Trudell Medical International presented the results of the study at the European Respiratory Society (ERS) International Congress Sept. 3-7 in London. Trudell…